Osteochondral Lesion of Talus Clinical Trial
Official title:
Clinical Efficacy of Arthroscopic Microfracture Combined With Local Injection of Platelet Rich Plasma Gel in Treatment of Osteochondral Lesion of the Talus: A Randomized Control Trial
The goal of this clinical trial is to learn if combined local injection of platelet rich plasma (PRP) gel adds clinical efficacy to isolated arthroscopic microfracture in treatment of osteochondral lesion of the talus (OLT). The interface integration of the injured area will also be assessed via radiographic follow-up. The main questions it aims to answer are: - Does arthroscopic microfracture combined with PRP gel injection improve ankle function of participants based on American Orthopedic Foot and Ankle Society (AOFAS) Score? - Does arthroscopic microfracture combined with PRP gel injection improve interface integration of the injured cartilage on magnetic resonance imaging (MRI)? Researchers will compare arthroscopic microfracture with concomitant local injection of PRP gel to isolated microfracture to see if intraoperative PRP gel injection adds clinical efficacy to isolated arthroscopic microfracture in treatment of OLT. Participants will: - Undergo either isolated arthroscopic microfracture or microfracture with intraoperative injection of PRP gel - Receive clinical follow-up 3, 6, 12, and 24 months after surgery and answer scales of ankle function assessment - Take MRI preoperatively and 6, 12 and 24 months after surgery
Status | Recruiting |
Enrollment | 70 |
Est. completion date | December 31, 2026 |
Est. primary completion date | January 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Chronic ankle pain, diagnosed as osteochondral lesion of the talus; - Lesion size = 1.5 cm2 or the diameter of the lesion = 1.5 cm; - Conservative treatment of at least 3 months fails to relieve symptoms; - Willingness to voluntarily participate in the trial and to sign informed consent. Exclusion Criteria: - Varus or valgus deformity of the ankle of more than 5 degrees; - Grade III injury of the lateral collateral ligament of ankle; - Chronic synovitis (rheumatoid arthritis, pigmented villous nodular synovitis, etc.); - Joint fibrosis, stiffness, and significantly restricted range of motion; - Evidence of moderate to severe knee osteoarthritis on plain radiographs; - Failure to complete the rehabilitation protocol as required; - Patient medically not fit for surgery, radiographs or MRI; - For women, pregnant, planning to be pregnant or lactating. |
Country | Name | City | State |
---|---|---|---|
China | Peking University Third Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University Third Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | American Orthopedic Foot and Ankle Society Score (AOFAS) | The scale of AOFAS score will be answered by participants during clinic follow-up preoperatively, and 3, 6, 12 and 24 months after surgery. The primary outcome measure will be the AOFAS collected 24 months post-surgery. | Pre-surgery and 3, 6, 12 and 24 months after surgery | |
Secondary | Foot and Ankle Outcome Score (FAOS) | The scale of FAOS score will be answered by participants during clinic follow-up preoperatively, and 3, 6, 12 and 24 months after surgery. | Pre-surgery and 3, 6, 12 and 24 months after surgery | |
Secondary | Ankle Activity Score (AAS) | The scale of AAS score will be answered by participants during clinic follow-up preoperatively, and 3, 6, 12 and 24 months after surgery. | Pre-surgery and 3, 6, 12 and 24 months after surgery | |
Secondary | Visual Analogue Scale (VAS) | The scale of VAS score will be answered by participants during clinic follow-up preoperatively, and 3, 6, 12 and 24 months after surgery. | Pre-surgery and 3, 6, 12 and 24 months after surgery | |
Secondary | Patient Satisfaction | Patient satisfaction will be graded as 0-10 and collected 24 months after surgery. | Final follow-up (24 months after surgery) | |
Secondary | Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) | MOCART score will be assessed on magnetic resonance imaging 12 and 24 months after surgery. | Twelve and 24 months after surgery | |
Secondary | Return-to-Sport Rate | The rate and time point of participants returning to sports will be continuously followed during clinic follow-up and will be overall collected 24 months after surgery. | Final follow-up (24 months after surgery) | |
Secondary | Complications | Complications, including infection,hematoma, stiffness, recurrent ankle pain will be continuously followed during clinic follow-up and will be overall collected 24 months after surgery. | Final follow-up (24 months after surgery) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04475341 -
Osteochondral Lesions Under 15mm2 of the Talus; is Iliac Crest Bone Marrow Aspirate Concentrate the Key to Success?
|
N/A | |
Enrolling by invitation |
NCT03856021 -
Microfracture vs. Microfracture and BMAC for Osteochondral Lesions of the Talus
|
N/A | |
Not yet recruiting |
NCT05476692 -
Clinical Outcome of Surgical Treatment for Osteochondral Lesions of the Talus
|
||
Active, not recruiting |
NCT02345564 -
Clinical and Radiological Results of Osteochondral Repair Using MaioRegen in Knee and Ankle Surgery
|
N/A | |
Active, not recruiting |
NCT01347892 -
DeNovo NT Ankle LDC Study
|
N/A | |
Active, not recruiting |
NCT03750253 -
Extracorporeal Shock Wave Therapy for Pain-Relief After Arthroscopy for Osteochondral Lesions of the Talus
|
N/A | |
Completed |
NCT04194970 -
Monitoring of Weight Bearing Protocols Via Mobile Application and Pressure Sensors.
|
N/A | |
Enrolling by invitation |
NCT02338375 -
Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product
|
Phase 0 | |
Withdrawn |
NCT05741983 -
AMIC vs. MFx in the Ankle
|
N/A | |
Enrolling by invitation |
NCT04132076 -
Treatment Outcome After Ankle Joint Surgeries
|